A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

Trial Profile

A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

Discontinued
Phase of Trial: Phase III

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Custirsen (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ENSPIRIT
  • Sponsors OncoGenex Pharmaceuticals; Teva Pharmaceutical Industries
  • Most Recent Events

    • 23 Feb 2017 According to an OncoGenex Pharmaceuticals Inc. media release, the company has discontinued the development of custirsen.
    • 23 Feb 2017 According to an OncoGenex Pharmaceuticals Inc. media release, status changed from recruiting to discontinued.
    • 26 Jan 2017 This trial has been completed in Italy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top